Sars-Cov-2 (Covid-19) Mrna-1273 (Bivalent Booster) Vaccine Dosage

Usual Adult Dose for COVID-19

For investigational use only

Booster Dose: 0.5 mL IM, at least 2 months after completing a primary vaccination series or booster dose with this or another authorized/approved coronavirus disease 2019 (COVID-19) vaccine.

Comments:

• The US FDA issued an Emergency Use Authorization (EUA) to allow the emergency use of this unapproved product for active immunization to prevent COVID-19. This product is not approved by the US FDA for this use.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Use: Active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) original and Omicron BA.4/BA.5 strains

Usual Pediatric Dose for COVID-19

For investigational use only

Booster Dose:
6 to 11 years: 0.25 mL IM, at least 2 months after completing a primary vaccination series with this or another authorized/approved COVID-19 vaccine.
12 years and older: 0.5 mL IM, at least 2 months after completing a primary vaccination series or booster dose with this or another authorized/approved COVID-19 vaccine.

Comments:

• The US FDA issued an EUA to allow the emergency use of this unapproved product for active immunization to prevent COVID-19. This product is not approved by the US FDA for this use.
• For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Use: Active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) original and Omicron BA.4/BA.5 strains

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Known history of severe allergic reactions (e.g., anaphylaxis) to the active component or any of the ingredients

Safety and efficacy of this formulation have not been established in patients younger than
6 years.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer IM.
• Gently swirl the vial between doses; do not shake.

Storage requirements:

• Store frozen between -15C to -50C (5F to -58F); store in original package to protect from light.
• Thaw each vial before use; once thawed, do not return vial to freezer.
• Thawed vials may be handled in room light conditions.
• Vials may be stored between 8C and 25C (46F to 77F) for a total of 24 hours.
• May store vials in refrigerator between 2C to 8C (36F to 46F) for up to 30 days prior to first use.
• In use vial (needle-punctured): Store between 2C to 25C (36F to 77F); discard vial 12 hours after first puncture.
• Do not refreeze.

Reconstitution/preparation techniques:

• Do not dilute.
• Consult the Fact Sheet for Health Care Providers.

Patient advice:

• Read the Fact Sheet for Recipients and Caregivers.
• To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer